{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:12:45Z","timestamp":1777101165427,"version":"3.51.4"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009041","name":"National Department of Health","doi-asserted-by":"publisher","award":["No award number"],"award-info":[{"award-number":["No award number"]}],"id":[{"id":"10.13039\/100009041","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Solidarity Response Fund NPC"},{"DOI":"10.13039\/100000880","name":"Michael and Susan Dell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000880","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Elma Vaccines and Immunization Foundation","award":["21-V0001"],"award-info":[{"award-number":["21-V0001"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-030342"],"award-info":[{"award-number":["INV-030342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes for Health","doi-asserted-by":"crossref","award":["K43TW011178-02"],"award-info":[{"award-number":["K43TW011178-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2017SF-1981"],"award-info":[{"award-number":["TMA2017SF-1981"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"South Africa Medical Research Council","award":["No award number"],"award-info":[{"award-number":["No award number"]}]},{"name":"National Research Foundation South Africa","award":["No award number"],"award-info":[{"award-number":["No award number"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clinical trials, support continued use, and thereby improve public confidence. The Sisonke study aimed to assess the safety and effectiveness of the Janssen Ad26.COV2.S vaccine among healthcare workers (HCWs) in South Africa. Here, we present the safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      In this open-label phase 3b implementation study among all eligible HCWs in South Africa registered in the national Electronic Vaccination Data System (EVDS), we monitored adverse events (AEs) at vaccination sites through self-reporting triggered by text messages after vaccination, healthcare provider reports, and active case finding. The frequency and incidence rate of non-serious and serious AEs were evaluated from the day of first vaccination (17 February 2021) until 28 days after the final vaccination in the study (15 June 2021). COVID-19 breakthrough infections, hospitalisations, and deaths were ascertained via linkage of the electronic vaccination register with existing national databases. Among 477,234 participants, 10,279 AEs were reported, of which 138 (1.3%) were serious AEs (SAEs) or AEs of special interest. Women reported more AEs than men (2.3% versus 1.6%). AE reports decreased with increasing age (3.2% for age 18\u201330 years, 2.1% for age 31\u201345 years, 1.8% for age 46\u201355 years, and 1.5% for age &gt; 55 years). Participants with previous COVID-19 infection reported slightly more AEs (2.6% versus 2.1%). The most common reactogenicity events were headache (\n                      <jats:italic>n =<\/jats:italic>\n                      4,923) and body aches (\n                      <jats:italic>n =<\/jats:italic>\n                      4,483), followed by injection site pain (\n                      <jats:italic>n =<\/jats:italic>\n                      2,767) and fever (\n                      <jats:italic>n =<\/jats:italic>\n                      2,731), and most occurred within 48 hours of vaccination. Two cases of thrombosis with thrombocytopenia syndrome and 4 cases of Guillain-Barr\u00e9 Syndrome were reported post-vaccination. Most SAEs and AEs of special interest (\n                      <jats:italic>n =<\/jats:italic>\n                      138) occurred at lower than the expected population rates. Vascular (\n                      <jats:italic>n =<\/jats:italic>\n                      37; 39.1\/100,000 person-years) and nervous system disorders (\n                      <jats:italic>n =<\/jats:italic>\n                      31; 31.7\/100,000 person-years), immune system disorders (\n                      <jats:italic>n =<\/jats:italic>\n                      24; 24.3\/100,000 person-years), and infections and infestations (\n                      <jats:italic>n =<\/jats:italic>\n                      19; 20.1\/100,000 person-years) were the most common reported SAE categories. A limitation of the study was the single-arm design, with limited routinely collected morbidity comparator data in the study setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We observed similar patterns of AEs as in phase 3 trials. AEs were mostly expected reactogenicity signs and symptoms. Furthermore, most SAEs occurred below expected rates. The single-dose Ad26.COV2.S vaccine demonstrated an acceptable safety profile, supporting the continued use of this vaccine in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04838795\" xlink:type=\"simple\">NCT04838795<\/jats:ext-link>\n                      ; Pan African Clinical Trials Registry\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=15686\" xlink:type=\"simple\">PACTR202102855526180<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004024","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:27:09Z","timestamp":1655818029000},"page":"e1004024","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6030-2359","authenticated-orcid":true,"given":"Simbarashe","family":"Takuva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-4208","authenticated-orcid":true,"given":"Azwidhwi","family":"Takalani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-2393","authenticated-orcid":true,"given":"Ishen","family":"Seocharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-8611","authenticated-orcid":true,"given":"Nonhlanhla","family":"Yende-Zuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9521-2692","authenticated-orcid":true,"given":"Tarylee","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5370-6600","authenticated-orcid":true,"given":"Imke","family":"Engelbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Faesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4826-7578","authenticated-orcid":true,"given":"Kentse","family":"Khuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1972-7229","authenticated-orcid":true,"given":"Valentina","family":"Trivella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-0723","authenticated-orcid":true,"given":"Jonathan","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-2604","authenticated-orcid":true,"given":"Jessica","family":"Opie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2885-3342","authenticated-orcid":true,"given":"Vernon","family":"Louw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2362-8752","authenticated-orcid":true,"given":"Pradeep","family":"Rowji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Groenewald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob E.","family":"Dorrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6669-9040","authenticated-orcid":true,"given":"Ria","family":"Laubscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-0699","authenticated-orcid":true,"given":"Harry","family":"Moultrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Fairall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Sanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-4386","authenticated-orcid":true,"given":"Linda","family":"Gail-Bekker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-5774","authenticated-orcid":true,"given":"Glenda","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-6486","authenticated-orcid":true,"given":"Ameena","family":"Goga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-234X","authenticated-orcid":true,"given":"Nigel","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Sisonke study team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"pmed.1004024.ref001","unstructured":"South African Medical Research Council. Report on weekly deaths in South Africa. Cape Town: South African Medical Research Council; 2021 [cited 2021 Nov 2]. Available from: https:\/\/www.samrc.ac.za\/reports\/report-weekly-deaths-south-africa."},{"issue":"23","key":"pmed.1004024.ref002","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"J Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"7854","key":"pmed.1004024.ref003","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"H Tegally","year":"2021","journal-title":"Nature"},{"key":"pmed.1004024.ref004","unstructured":"National Institute for Occupational Health. COVID-19 sentinel hospital surveillance weekly update on hospitalized HCWs. Update: Week 19, 2021. Johannesburg: National Institute for Occupational Health; 2021 [cited 2021 Nov 20]. Available from: https:\/\/www.nioh.ac.za\/wp-content\/uploads\/2021\/05\/COVID_HCW_Report_Week19of2021-24-May-2021_Final_.pdf."},{"key":"#cr-split#-pmed.1004024.ref005.1","unstructured":"Janssen Biotech. Fact sheet for recipients and caregivers: emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Silver Spring (MD): Food and Drug Administration"},{"key":"#cr-split#-pmed.1004024.ref005.2","unstructured":"2021 [cited 2021 Nov 16]. Available from: https:\/\/www.fda.gov\/media\/146305\/download."},{"key":"pmed.1004024.ref006","unstructured":"Our World in Data. COVID-19 vaccine doses administered by manufacturer, United States. Our World in Data; 2021 [cited 2021 Nov 20]. Available from: https:\/\/ourworldindata.org\/grapher\/covid-vaccine-doses-by-manufacturer?country=~USA."},{"issue":"36","key":"pmed.1004024.ref007","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"TT Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"#cr-split#-pmed.1004024.ref008.1","unstructured":"Food and Drug Administration. Vaccines and related biological products advisory committee meeting: February 26, 2021. FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. Silver Spring (MD): Food and Drug Administration"},{"key":"#cr-split#-pmed.1004024.ref008.2","unstructured":"2021 [cited 2021 Nov 20]. Available from: https:\/\/www.fda.gov\/media\/146217\/download."},{"key":"pmed.1004024.ref009","unstructured":"Law B, Sturkenboom M. D2.3 priority list of adverse events of special interest: COVID-19. V2.0. Safety Platform for Emergency Vaccines; 2020 [cited 2021 Nov 15]. Available from: https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2020\/06\/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf."},{"key":"pmed.1004024.ref010","unstructured":"Rosenblum H. COVID-19 vaccines in adults: benefit-risk discussion. Atlanta: Centers for Disease Control and Prevention; 2021 [cited 2021 Nov 15]. Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-07\/05-COVID-Rosenblum-508.pdf."},{"key":"pmed.1004024.ref011","unstructured":"South African Health Products Regulatory Authority. SAHPRA statement\u2014update on Sisonke phase 3B implementation study. Pretoria: South African Health Products Regulatory Authority; 2021 [cited 2021 Nov 16]. Available from: https:\/\/www.sahpra.org.za\/wp-content\/uploads\/2021\/04\/SAHPRA-Statement-on-pausing-of-the-Sisonke-study-19-April-.pdf."},{"issue":"6","key":"pmed.1004024.ref012","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMc2107920","article-title":"Thromboembolic events in the South African Ad26.COV2.S vaccine study","volume":"385","author":"S Takuva","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004024.ref013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12245-009-0093-z","article-title":"Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis","volume":"2","author":"V Manivannan","year":"2009","journal-title":"Int J Emerg Med"},{"key":"pmed.1004024.ref014","unstructured":"Law B. SO2-D2.5.2.1\u2014AESI case definition companion guide for 1st tier AESI: anaphylaxis. Safety Platform for Emergency Vaccines; 2021 [cited 2021 Nov 16]. Available from: https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2021\/03\/SPEAC_D2.5.2.1_Anaphylaxis-Case-Definition-Companion-Guide_V1.0-12070-1.pdf."},{"issue":"8","key":"pmed.1004024.ref015","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1474-4422(10)70144-7","article-title":"Stroke incidence in rural and urban Tanzania: a prospective, community-based study","volume":"9","author":"R Walker","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"pmed.1004024.ref016","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2458-5-23","article-title":"Epidemiology of acute coronary syndromes in a Mediterranean country; aims, design and baseline characteristics of the Greek study of acute coronary syndromes (GREECS)","volume":"5","author":"C Pitsavos","year":"2005","journal-title":"BMC Public Health"},{"key":"pmed.1004024.ref017","unstructured":"Brighton Collaboration. Brighton Collaboration case definitions. Decatur (GA): Task Force for Global Health; 2021 [cited 2021 Nov 16]. Available from: https:\/\/brightoncollaboration.us\/category\/pubs-tools\/case-definitions\/."},{"issue":"5","key":"pmed.1004024.ref018","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/pds.5419","article-title":"Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries","volume":"31","author":"E Burn","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pmed.1004024.ref019","unstructured":"Dorrington R, Bradshaw D, Laubscher R, Nannan N. Rapid mortality surveillance report 2018. Cape Town: South African Medical Research Council; 2020 [cited 2022 Nov 15]. Available from: https:\/\/www.samrc.ac.za\/sites\/default\/files\/files\/2020-03-02\/RapidMortalitySurveillanceReport2018.pdf."},{"issue":"10330","key":"pmed.1004024.ref020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(22)00007-1","article-title":"Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study","volume":"399","author":"LG Bekker","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"pmed.1004024.ref021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/trstmh\/tru167","article-title":"Sex-based differences in immune function and responses to vaccination","volume":"109","author":"SL Klein","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pmed.1004024.ref022","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"KL Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"3","key":"pmed.1004024.ref023","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.it.2013.10.006","article-title":"SeXX matters in immunity","volume":"35","author":"JG Markle","year":"2014","journal-title":"Trends Immunol"},{"issue":"10267","key":"pmed.1004024.ref024","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"MN Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"pmed.1004024.ref025","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"J Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"pmed.1004024.ref026","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"EE Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"pmed.1004024.ref027","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"C Manisty","year":"2021","journal-title":"Lancet"},{"key":"pmed.1004024.ref028","doi-asserted-by":"crossref","first-page":"n308","DOI":"10.1136\/bmj.n308","article-title":"Covid-19: people who have had infection might only need one dose of mRNA vaccine","volume":"372","author":"J. Wise","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"pmed.1004024.ref029","first-page":"535","article-title":"Recommendations for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia","volume":"111","author":"BF Jacobson","year":"2021","journal-title":"S Afr Med J"},{"issue":"11b","key":"pmed.1004024.ref030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7196\/SAMJ.2019.v109i11b.14273","article-title":"Burden of disease in South Africa: protracted transitions driven by social pathologies","volume":"109","author":"D Bradshaw","year":"2019","journal-title":"S Afr Med J"},{"issue":"3","key":"pmed.1004024.ref031","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(20)30359-3","article-title":"The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis","volume":"8","author":"J Dorward","year":"2021","journal-title":"Lancet HIV"},{"key":"pmed.1004024.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2021.05.001","article-title":"Thrombotic thrombocytopenic purpura after Ad26.COV2-S vaccination","volume":"49","author":"A Yocum","year":"2021","journal-title":"Am J Emerg Med"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:27:53Z","timestamp":1655818073000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004024"}},"subtitle":[],"editor":[{"given":"Amitabh Bipin","family":"Suthar","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004024","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.20.21267967","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]}}}